Meridian Bioscience gets FDA clearance for molecular group B strep test
Diagnostic test maker Meridian Bioscience (NASDAQ:VIVO) has received regulatory clearance of a molecular diagnostics test for group B streptococcus. The group B strep test is the second in the Cincinnati-area company’s illumigene line of molecular diagnostic tests to be cleared by the U.S. Food and Drug Administration. The illumigene product line is key to Meridian’s […]